Zealand Pharma: Bryan Garnier raises target price
(CercleFinance.com) - Bryan Garnier maintains a "buy" rating on Zealand Pharma, while raising its target price on the share from 133 Danish kronor to 155 Danish kronor, after the Danish biotechnology company's Capital Market Days.
In a report sent to clients, the broker says that the company is "on the right track" by moving away from its past dependence on Sanofi.
"A new indication for Dasiglucagon in the treatment of congenital hyperinsulinism even opens a window towards a small but lucrative new rare disease market that Zealand might exploit by itself," it said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
In a report sent to clients, the broker says that the company is "on the right track" by moving away from its past dependence on Sanofi.
"A new indication for Dasiglucagon in the treatment of congenital hyperinsulinism even opens a window towards a small but lucrative new rare disease market that Zealand might exploit by itself," it said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.